NOVAVAX
Information

Novavax

ISIN
US6700024010
Ticker
NVAX
ISIN
US6700024010
Ticker
NVAX
New Post
$53.67
- $0.40
-0.74%

Information

mid cap stock
Novavax, Inc., along with its wholly owned subsidiaries, Novavax AB and Novavax CZ, is a biotechnology company. The Company promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).
Employees
1,541
Industries
Biotechnology & Drugs
Sector
Health Care

Community

Financials

52W span
$34.88
$277.80
Market Cap
$4.21B
Beta
1.57755
Free Float
77.77M
Shares outstanding
78.13M

Analyst Ratings

Target Price
$155.17
This security is covered by 7 analysts
Buy
5
Hold
1
Sell
1

Activities

Trending